Overview:
KRAS (KRAS Mutation RT-PCR) TestIntroduction: The KRAS (KRAS Mutation RT-PCR) Test is a diagnostic tool designed to detect KRAS codon 12 and codon 13 mutations in tissue preserved in formalin-fixed paraffin-embedded (FFPE) or tissue preservative, facilitating the diagnosis of cancer. Associated with colorectal or pancreatic cancer, these oncologic conditions present with abnormal growths, weight loss, and severe complications like metastasis if untreated, particularly in individuals with genetic predisposition or chronic inflammation. Per the 2023 National Comprehensive Cancer Network guidelines, the test employs molecular pathology with real-time PCR technology, delivering detailed mutation identification over 3-5 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in molecular pathology settings. This diagnostic falls under cancer screening and targets individuals with gastrointestinal or systemic symptoms, addressing the challenge of accurate mutation classification to guide targeted therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its tissue-based approach ensures reliable detection.
Other Names: KRAS Mutation Test.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: Introduced in the 2000s by various molecular labs, this test advanced cancer diagnostics by standardizing KRAS mutation detection.
Purpose: The test detects KRAS codon 12 mutations and KRAS codon 13 mutations to guide cancer diagnosis, assess oncologic status, and inform treatment and prevention strategies.
Test Parameters: Presence of KRAS codon 12 mutations and KRAS codon 13 mutations, detected with high specificity to indicate cancerous activity, typically observable in tissue at altered genetic patterns during active disease, with mutation prevalence and type assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected areas.
Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report abnormal growths, weight loss, or recent tumor development.
Specimen: Tissue 0.5-2 cma³, collected as FFPE or Tissue Preservative, transported indefinitely to maintain sample viability.
Sample Stability at Room Temperature: Indefinite with proper preservation to maintain DNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: Not refrigerated, as FFPE or preserved samples are stable at room temperature with proper storage.
Sample Stability at Frozen: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.
Medical History: Patients should provide details on abnormal growths, weight loss, prior cancer, or family history of oncologic disease, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves tissue processing, DNA extraction, real-time PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3-5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays in processing, improper preservation, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.
Clinical Significance: A positive result indicates possible cancer with KRAS mutation, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.
Specialist Consultation: Oncologists or gastroenterologists should be consulted for case management, treatment planning, and coordination with cancer programs.
Additional Supporting Tests: CT scan, biopsy review, or EGFR testing for confirmation.
Test Limitations: The test may produce false negatives in low tumor burden or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: NCCN Guidelines 2023, Journal of Molecular Diagnostics 2024, Molecular Pathology 2025.
